Monopar Therapeutics Net Worth

Monopar Therapeutics Net Worth Breakdown

  MNPR
The net worth of Monopar Therapeutics is the difference between its total assets and liabilities. Monopar Therapeutics' net worth represents the value of the company's equity or ownership interest. In other words, it is the amount of money that would be left over if all of Monopar Therapeutics' assets were sold and all of its debts were paid off. Net worth is sometimes referred to as shareholder's equity or book value. Monopar Therapeutics' net worth can be used as a measure of its financial health and stability which can help investors to decide if Monopar Therapeutics is a good investment. It is also essential in determining the company's creditworthiness and ability to secure financing before investing in Monopar Therapeutics stock.

Monopar Therapeutics Net Worth Analysis

Monopar Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Monopar Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Monopar Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Monopar Therapeutics' net worth analysis. One common approach is to calculate Monopar Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Monopar Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Monopar Therapeutics' net worth. This approach calculates the present value of Monopar Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Monopar Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Monopar Therapeutics' net worth. This involves comparing Monopar Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Monopar Therapeutics' net worth relative to its peers.

Enterprise Value

19.01 Million

17914217.20.19.-21%-88%15%-5%100%
To determine if Monopar Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Monopar Therapeutics' net worth research are outlined below:
Monopar Therapeutics is way too risky over 90 days horizon
Monopar Therapeutics appears to be risky and price may revert if volatility continues
Net Loss for the year was (8.4 M) with profit before overhead, payroll, taxes, and interest of 0.
Monopar Therapeutics currently holds about 16.46 M in cash with (7.86 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.29.
Monopar Therapeutics has a frail financial position based on the latest SEC disclosures
Roughly 37.0% of the company outstanding shares are owned by corporate insiders
Latest headline from MacroaxisInsider: Disposition of 9957 shares by Tsuchimoto Kim R of Monopar Therapeutics subject to Rule 16b-3
Monopar Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Monopar Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Monopar Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
28th of March 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
28th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Monopar Therapeutics Target Price Consensus

Monopar target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Monopar Therapeutics' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
   4  Strong Buy
Strong Buy50.0%Buy50.0%Hold0.0%Sell0.0%Strong Sell0.0%
Most Monopar analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Monopar stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Monopar Therapeutics, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice   Exposure   Valuation

Monopar Therapeutics Target Price Projection

Monopar Therapeutics' current and average target prices are 32.84 and 42.00, respectively. The current price of Monopar Therapeutics is the price at which Monopar Therapeutics is currently trading. On the other hand, Monopar Therapeutics' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.

Current Price

Monopar Therapeutics Market Quote on 28th of February 2025

Low Price30.25Odds
High Price32.84Odds

32.84

Target Price

Analyst Consensus On Monopar Therapeutics Target Price

Low Estimate38.22Odds
High Estimate46.62Odds

42.0

Historical Lowest Forecast  38.22 Target Price  42.0 Highest Forecast  46.62
Note that most analysts generally publish their price targets in research reports on specific companies, along with recommendations for the company's stock.Although price targets are often quoted in the financial news media, there could be a delay between the publication of the latest analyst outlook on Monopar Therapeutics and the information provided on this page.

Know Monopar Therapeutics' Top Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Monopar Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Monopar Therapeutics backward and forwards among themselves. Monopar Therapeutics' institutional investor refers to the entity that pools money to purchase Monopar Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Goss Wealth Management Llc2024-12-31
600
Wells Fargo & Co2024-12-31
250
Sbi Securities Co Ltd2024-12-31
100.0
Bank Of America Corp2024-12-31
28.0
Federation Des Caisses Desjardins Du Quebec2024-09-30
16.0
Gerber Llc2024-09-30
0.0
Northern Trust Investments N A2024-12-31
0.0
Hhg Plc2024-12-31
M
Adage Capital Partners Gp Llc
599.2 K
Ra Capital Management, Llc2024-12-31
511.2 K
Point72 Asset Management, L.p.2024-12-31
167.9 K
Note, although Monopar Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Follow Monopar Therapeutics' market capitalization trends

The company currently falls under 'Small-Cap' category with a current market capitalization of 184.6 M.

Market Cap

26.95 Million

Project Monopar Therapeutics' profitablity

Last ReportedProjected for Next Year
Return On Tangible Assets(1.32)(1.38)
Return On Capital Employed(1.82)(1.73)
Return On Assets(1.32)(1.38)
Return On Equity(1.73)(1.64)
When accessing Monopar Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Monopar Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Monopar Therapeutics' profitability and make more informed investment decisions.

Evaluate Monopar Therapeutics' management efficiency

Monopar Therapeutics has return on total asset (ROA) of (0.5967) % which means that it has lost $0.5967 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.1204) %, meaning that it created substantial loss on money invested by shareholders. Monopar Therapeutics' management efficiency ratios could be used to measure how well Monopar Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of 02/28/2025, Return On Tangible Assets is likely to drop to -1.38. In addition to that, Return On Capital Employed is likely to grow to -1.73. At this time, Monopar Therapeutics' Total Assets are relatively stable compared to the past year. As of 02/28/2025, Total Current Assets is likely to grow to about 11.2 M, while Non Current Assets Total are likely to drop slightly above 10.8 K.
Last ReportedProjected for Next Year
Book Value Per Share 0.35  0.66 
Tangible Book Value Per Share 0.35  0.66 
Enterprise Value Over EBITDA 46.65  44.32 
Price Book Value Ratio 5.08  4.82 
Enterprise Value Multiple 46.65  44.32 
Price Fair Value 5.08  4.82 
Enterprise Value20 M19 M
Effective leadership at Monopar Therapeutics drives its competitive edge in the market. Our analysis focuses on how this translates to financial performance and stock value.
Return On Equity
(1.12)
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Monopar Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Monopar Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Monopar Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Tsuchimoto Kim R over a week ago
Disposition of 9957 shares by Tsuchimoto Kim R of Monopar Therapeutics subject to Rule 16b-3
 
Klausner Arthur J over three weeks ago
Disposition of 2533 shares by Klausner Arthur J of Monopar Therapeutics subject to Rule 16b-3
 
Cittadine Andrew over a month ago
Disposition of 13841 shares by Cittadine Andrew of Monopar Therapeutics subject to Rule 16b-3
 
Cittadine Andrew over a month ago
Acquisition by Cittadine Andrew of 1791 shares of Monopar Therapeutics subject to Rule 16b-3
 
Rioux Patrice over a month ago
Acquisition by Rioux Patrice of 2000 shares of Monopar Therapeutics at 22.0 subject to Rule 16b-3
 
Robinson Chandler over a month ago
Disposition of 4895 shares by Robinson Chandler of Monopar Therapeutics subject to Rule 16b-3
 
Cittadine Andrew over two months ago
Acquisition by Cittadine Andrew of 12000 shares of Monopar Therapeutics at 0.76 subject to Rule 16b-3
 
Cittadine Andrew over two months ago
Disposition of 535 shares by Cittadine Andrew of Monopar Therapeutics at 6.74 subject to Rule 16b-3
 
Christopher Starr over two months ago
Disposition of 2533 shares by Christopher Starr of Monopar Therapeutics subject to Rule 16b-3
 
Tacticgem Llc over two months ago
Disposition of 1433334 shares by Tacticgem Llc of Monopar Therapeutics subject to Rule 16b-3
 
Cittadine Andrew over three months ago
Acquisition by Cittadine Andrew of 12000 shares of Monopar Therapeutics at 0.6397 subject to Rule 16b-3
 
Cittadine Andrew over three months ago
Disposition of 1791 shares by Cittadine Andrew of Monopar Therapeutics subject to Rule 16b-3

Monopar Therapeutics Corporate Filings

8K
24th of February 2025
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
14th of February 2025
Other Reports
ViewVerify
12th of February 2025
Other Reports
ViewVerify
7th of February 2025
Other Reports
ViewVerify
Monopar Therapeutics time-series forecasting models is one of many Monopar Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Monopar Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Monopar Therapeutics Earnings per Share Projection vs Actual

Monopar Therapeutics Corporate Executives

Elected by the shareholders, the Monopar Therapeutics' board of directors comprises two types of representatives: Monopar Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Monopar. The board's role is to monitor Monopar Therapeutics' management team and ensure that shareholders' interests are well served. Monopar Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Monopar Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Christopher StarrCoFounder BoardProfile
Kim CPASecretary, CFOProfile
Karthik CFAPrincipal CFOProfile

Additional Tools for Monopar Stock Analysis

When running Monopar Therapeutics' price analysis, check to measure Monopar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Monopar Therapeutics is operating at the current time. Most of Monopar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Monopar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Monopar Therapeutics' price. Additionally, you may evaluate how the addition of Monopar Therapeutics to your portfolios can decrease your overall portfolio volatility.
News Freq…Investor S…